CTOs on the Move

Alltrna

www.alltrna.com

 
Alltrna is the first transfer RNA (tRNA) platform company, and our mission is to unlock tRNA biology and pioneer tRNA therapeutics to regulate the protein universe and resolve disease. Founded at Flagship Labs in 2018, Alltrna has mapped tRNA biology to systematically design tRNA medicines and encode a completely new, unifying approach to treating both rare and common human diseases driven by shared genetic mutations. Alltrna`s platform combines internal expertise and proprietary machine learning tools to unlock the entire tRNA biology space. We have an unprecedented opportunity to advance a single tRNA medicine to restore disrupted protein production, regardless of ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.alltrna.com
  • 55 Cambridge Parkway Suite 800e
    Cambridge, MA USA 02142
  • Phone: n/a

Executives

Name Title Contact Details
William Kiesman
 Chief Technology Officer Profile

Similar Companies

Reichert Analytical Instruments

Reichert Analytical Instruments is a Depew, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kali-Extracts

Making lives better with natural botanical therapies derived from our patented extraction process

Bioinformatics Solutions

Bioinformatics Solutions Inc. is a Waterloo, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avantra Biosciences FKA Decision Biomarkers

Avantra Biosciences FKA Decision Biomarkers, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paragon Biosciences

Paragon Biosciences invests in and launches biopharmaceutical companies to develop novel therapies for severe medical conditions which do not yet have adequate treatments. Our mission is to help people live longer, healthier lives. Paragon advances that mission through its contribution of Bioscience Innovation Capital(TM): For rare and complex diseases, Paragon analyzes the viability of potential therapies, invests in new biopharmaceutical companies to further develop promising treatments, catalyzes the progress of its portfolio companies through early-incubation services, and provides clinical and regulatory guidance by a team with a near-perfect track record of first-cycle novel drug approvals.